Cerebrospinal Fluid and Serum Neuron‐Specific Enolase in Niemann‐Pick Disease Type C1
American Journal of Medical Genetics Part A · 2025
DOI: 10.1002/ajmg.a.63970 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Cameron J Padilla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of H…. Hauptthemen laut MEDLINE: Niemann-Pick Disease, Type C, Phosphopyruvate Hydratase. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eunice Kennedy Shriver National Institute of Child Health and Human Development, Support of Accelerated Research for Niemann-Pick Type C, Intramural NIH HHS.
Abstract (Originalsprache)
Niemann‐Pick disease, type C1 (NPC1) is an ultra rare, autosomal recessive disorder characterized by impaired intracellular cholesterol trafficking. This study assessed neuron‐specific enolase (NSE) as a biomarker for disease status and treatment response in individuals with NPC1. We also evaluated the concordance between serum and cerebrospinal fluid (CSF) NSE measurements. A total of 34 individuals with NPC1 were included in this analysis. Overall, 10 participants were used to compare concurrent samples of CSF and serum NSE. NSE levels were correlated with indexes of disease severity (Annual Severity Increment Score [ASIS] and age of neurological onset) and disease burden (NPC Neurological Severity Score [NSS]). NSE was elevated in CSF, but paired CSF/serum samples were not correlated ( r s = −0.16, p = 0.64). Additionally, no significant correlations were observed between serum NSE levels and clinical measures of either disease burden or severity. CSF NSE values showed a significant positive association with the ASIS ( r s = 0.37, p = 0.0291) but no association with age of neurological onset or NPC NSSs. Longitudinal analysis of nine participants showed a significant ( p = 0.0317) decrease in CSF NSE levels after initiation of intrathecal 2‐hydroxypropyl‐β‐cyclodextrin (IT HPβCD) therapy. This study suggests that CSF NSE may have some utility as a biomarker in NPC1 therapeutic trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, USA.
- Department of Pediatrics, Rush University Medical Center, Chicago, Illinois, USA.
- Department of Pediatrics, Neurological Sciences and Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA.
ORCID-Profile: Forbes D Porter
Förderung
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Support of Accelerated Research for Niemann-Pick Type C
- Intramural NIH HHS
- Ara Parseghian Medical Research Foundation
- Ara Parseghian Medical Research Fund
Zitieren
APA
Padilla, C. J., Alexander, D. M., Labor, D. A., Albert, O. K., Robbins, K. P., Berry-Kravis, E., & Porter, F. D. (2025). Cerebrospinal Fluid and Serum Neuron‐Specific Enolase in Niemann‐Pick Disease Type C1. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63970
Vancouver
Padilla CJ, Alexander DM, Labor DA, Albert OK, Robbins KP, Berry-Kravis E, et al. Cerebrospinal Fluid and Serum Neuron‐Specific Enolase in Niemann‐Pick Disease Type C1. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.63970
BibTeX
@article{Padilla2025,
author = {Padilla, Cameron J and Alexander, Derek M and Labor, Desiree A and Albert, Orsolya K and Robbins, Kendall P and Berry-Kravis, Elizabeth and Porter, Forbes D},
title = {Cerebrospinal Fluid and Serum Neuron‐Specific Enolase in Niemann‐Pick Disease Type C1},
journal = {American Journal of Medical Genetics Part A},
year = {2025},
doi = {10.1002/ajmg.a.63970}
}
EUVIMED